Holen Sie sich die Stockscreener-App
15.60
0.39%
0.06
Handel nachbörslich:
15.60
Schlusskurs vom Vortag:
$15.54
Offen:
$15.7
24-Stunden-Volumen:
145.38K
Relative Volume:
0.82
Marktkapitalisierung:
$569.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.78%
1M Leistung:
+6.85%
6M Leistung:
-1.08%
1J Leistung:
-23.38%
1-Tages-Spanne:
$15.42
$16.13
1-Wochen-Bereich:
$13.62
$16.13
52-Wochen-Spanne:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
15.60 | 567.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Rapport Therapeutics Inc. stock prediction for this weekJuly 2025 Levels & Weekly High Momentum Picks - Newser
Can Rapport Therapeutics Inc. hit a new high this monthMarket Rally & Entry Point Confirmation Alerts - Newser
How to manage a losing position in Rapport Therapeutics Inc. [Profit Target]Risk Controlled Swing Trade Alerts - Newser
How hedge fund analytics apply to Rapport Therapeutics Inc. stockJuly 2025 Fed Impact & Weekly High Return Opportunities - Newser
Will Rapport Therapeutics Inc. rebound enough to break evenFree Reliable Chart-Based Trade Entries - Newser
Published on: 2025-08-12 21:34:00 - Newser
Chart based exit strategy for Rapport Therapeutics Inc.Momentum Detection with Entry Optimization - Newser
How to manage a losing position in Rapport Therapeutics Inc.Strategy Builder for Growth Focused Traders - Newser
Published on: 2025-08-12 06:02:16 - Newser
Why Rapport Therapeutics Inc. stock attracts strong analyst attentionSecure Asset Flow and Trend Pattern Analysis - Newser
What momentum shifts mean for Rapport Therapeutics Inc.Reversal Signal Prediction Based on Volume - Newser
Market reaction to Rapport Therapeutics Inc.’s recent newsTrade Safety Matrix for Conservative Traders - Newser
What Fibonacci levels say about Rapport Therapeutics Inc. reboundFree Multi-Bagger Potential Stock Forecast Tools - Newser
Rapport Therapeutics Inc.’s volatility index tracking explainedMarket Downturn Defense Strategy Analysis - Newser
Candlestick signals on Rapport Therapeutics Inc. stock todayReal Time Trade Execution Alert Plan - Newser
Chart overlay techniques for tracking Rapport Therapeutics Inc.Short-Term Growth Watch with Signal Prediction - Newser
Comparing Rapport Therapeutics Inc. in custom built stock radarsFree Risk-Adjusted Picks With Exit Strategy - Newser
What is HC Wainwright’s Estimate for RAPP Q2 Earnings? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at HC Wainwright - Defense World
Rapport Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapport Therapeutics' Q2 2025 Update: RAP-219's Precision Neuroscience Potential and September 2025 Catalyst - AInvest
Rapport (RAPP) Q2 Net Loss Widens 47% - AOL.com
Rapport Therapeutics reports Q2 EPS (75c), consensus (79c) - TipRanks
Rapport Therapeutics sees cash runway through end of 2026 - TipRanks
Rapport Therapeutics Reports Q2 2025 Financials and Business Update. - AInvest
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update - GlobeNewswire
Press Release: Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update - 富途牛牛
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates Rapport Therapeutics at Buy With $31 Price Target - MarketScreener
Is Rapport Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Community Entry Consensus Trade Ideas - Newser
Bank of New York Mellon Corp Acquires 15,514 Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) - Defense World
Applying chart zones and confluence areas to Rapport Therapeutics Inc.Free Trade Setups With Clear Risk Limits - Newser
Rapport Therapeutics Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
AI Indicators Detect Buy Opportunity in Rapport Therapeutics Inc.Community Verified Stock Suggestions Drive Volume - metal.it
Is Rapport Therapeutics Inc. a good long term investmentFree Advanced Stock Screener Access - Jammu Links News
What institutional investors are buying Rapport Therapeutics Inc. stockUnlock expert insights for smarter investing - Jammu Links News
Is Rapport Therapeutics Inc. a growth stock or a value stockConsistently superior profits - Jammu Links News
Does Rapport Therapeutics Inc. stock perform well during market downturnsUnmatched market performance - Jammu Links News
How does Rapport Therapeutics Inc. generate profit in a changing economyAchieve rapid portfolio growth with expert help - Jammu Links News
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):